TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features
- PMID: 20562851
- PMCID: PMC3413944
- DOI: 10.1038/modpathol.2010.120
TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features
Abstract
TMPRSS2-ERG gene rearrangement is seen in about half of clinically localized prostate cancers, yet controversy exists with regard to its prognostic implications. Similarly, the relationship of TMPRSS2-ERG fusion to Gleason score and morphology remains uncertain. We assigned Gleason scores and recorded morphological features for 521 clinically localized prostate cancers sampled in triplicate and arrayed in eight tissue microarray blocks. Fluorescence in situ hybridization was performed to delineate TMPRSS2-ERG aberrations. Using maximum Gleason score, based on three core evaluation, and overall Gleason score, based on prostatectomy sections, Fisher's exact test was performed for tumors with TMPRSS2-ERG translocation/deletion, copy number increase (≥ 3) of the TMPRSS2-ERG region without translocation/deletion, and copy number increase and concomitant translocation/deletion. In all, 217 (42%) translocation/deletion and 30 (5.9%) copy number increase-alone cases were detected. Among 217 translocation/deletion cases, 32 had translocation/deletion with copy number increase. In all, 237, 200, and 75 cancers had maximum core-specific Gleason score of 6, 7, and 8-10, respectively. Tumors with translocation/deletion tended toward lower Gleason scores than those without (P=0.002) with similar results for overall Gleason score (P=0.02); copy number increase cases tended toward higher Gleason scores than those without (P<0.001). Gleason score of 8-10 tumors demonstrated lower odds of translocation/deletion (odds ratio (OR) 0.38; 95% CI 0.21-0.68) and higher odds of copy number increase alone (OR 7.33; 95% CI 2.65-20.31) or copy number increase+translocation/deletion (OR 3.03; 95% CI 1.12-8.15) relative to Gleason score of <7 tumors. No significant difference in TMPRSS2-ERG incidence was observed between patients with and without cribriform glands, glomerulations, signet-ring cells, or intraductal cancer (P=0.821, 0.095, 0.132, 0.375). TMPRSS2-ERG gene fusion is associated with lower core-specific and overall Gleason scores and not with high-grade morphologies. Conversely, TMPRSS2-ERG copy number increase, with or without rearrangement, is associated with higher Gleason score. These findings indicate that translocation/deletion of TMPRSS2-ERG is not associated with histological features of aggressive prostate cancer.
Figures







Similar articles
-
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.Mod Pathol. 2008 Dec;21(12):1451-60. doi: 10.1038/modpathol.2008.96. Epub 2008 May 23. Mod Pathol. 2008. PMID: 18500259
-
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.Mod Pathol. 2011 Nov;24(11):1511-20. doi: 10.1038/modpathol.2011.111. Epub 2011 Jul 8. Mod Pathol. 2011. PMID: 21743434 Free PMC article.
-
[TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):392-6. Zhonghua Bing Li Xue Za Zhi. 2011. PMID: 21914348 Chinese.
-
Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.Asian J Androl. 2020 Mar-Apr;22(2):200-207. doi: 10.4103/aja.aja_45_19. Asian J Androl. 2020. PMID: 31210145 Free PMC article.
-
Association Between ERG/PTEN Genes and Pathologic Parameters of Prostate Cancer With an Emphasis on Gleason Score: A Literature Review.Cancer Diagn Progn. 2023 May 3;3(3):291-296. doi: 10.21873/cdp.10214. eCollection 2023 May-Jun. Cancer Diagn Progn. 2023. PMID: 37168967 Free PMC article. Review.
Cited by
-
Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.Horm Cancer. 2017 Feb;8(1):28-48. doi: 10.1007/s12672-016-0279-9. Epub 2017 Jan 3. Horm Cancer. 2017. PMID: 28050800 Free PMC article.
-
Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.BMC Cancer. 2022 May 5;22(1):494. doi: 10.1186/s12885-022-09559-4. BMC Cancer. 2022. PMID: 35513774 Free PMC article.
-
African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8. J Urol. 2019. PMID: 31107158 Free PMC article.
-
Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.Am J Clin Pathol. 2011 Jul;136(1):98-107. doi: 10.1309/AJCPZ7WBU9YXSJPE. Am J Clin Pathol. 2011. PMID: 21685037 Free PMC article.
-
Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood.Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a030387. doi: 10.1101/cshperspect.a030387. Cold Spring Harb Perspect Med. 2018. PMID: 29229666 Free PMC article. Review.
References
-
- Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648. - PubMed
-
- Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596–4599. - PubMed
-
- Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882–888. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical